Shares of Shire PLC (NASDAQ:SHPG) have received an average recommendation of “Buy” from the twenty-four research firms that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $223.01.

Several equities research analysts recently issued reports on the company. HSBC Holdings plc cut Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday, May 19th. Royal Bank Of Canada set a $221.00 price target on Shire PLC and gave the company a “buy” rating in a research note on Thursday, May 18th. Sanford C. Bernstein cut Shire PLC from an “outperform” rating to a “market perform” rating and cut their price target for the company from $209.22 to $161.09 in a research note on Thursday, May 25th. Barclays PLC began coverage on Shire PLC in a research note on Tuesday, March 7th. They issued an “overweight” rating for the company. Finally, Liberum Capital began coverage on shares of Shire PLC in a research report on Thursday, March 9th. They set a “buy” rating for the company.

COPYRIGHT VIOLATION NOTICE: “Shire PLC (SHPG) Given Consensus Rating of “Buy” by Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/06/27/shire-plc-shpg-given-consensus-rating-of-buy-by-analysts.html.

Several hedge funds and other institutional investors have recently made changes to their positions in SHPG. Vanguard Group Inc. increased its position in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after buying an additional 13,665 shares during the period. BlackRock Inc. increased its position in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares during the period. Janus Capital Management LLC increased its position in shares of Shire PLC by 10.7% in the first quarter. Janus Capital Management LLC now owns 1,365,226 shares of the biopharmaceutical company’s stock valued at $237,854,000 after buying an additional 132,446 shares during the period. Boston Partners increased its position in shares of Shire PLC by 80.7% in the first quarter. Boston Partners now owns 1,359,151 shares of the biopharmaceutical company’s stock valued at $236,805,000 after buying an additional 606,814 shares during the period. Finally, Bank of America Corp DE increased its position in shares of Shire PLC by 19.7% in the first quarter. Bank of America Corp DE now owns 1,326,114 shares of the biopharmaceutical company’s stock valued at $231,049,000 after buying an additional 218,291 shares during the period. Institutional investors own 20.93% of the company’s stock.

Shares of Shire PLC (SHPG) traded down 0.44% during trading on Tuesday, hitting $172.61. The stock had a trading volume of 902,516 shares. Shire PLC has a 12-month low of $161.09 and a 12-month high of $209.22. The stock has a market capitalization of $51.41 billion, a P/E ratio of 177.04 and a beta of 1.57. The stock’s 50-day moving average is $176.62 and its 200-day moving average is $174.09.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.22 by $0.41. The business had revenue of $3.57 billion during the quarter. Shire PLC had a return on equity of 13.05% and a net margin of 2.14%. The company’s quarterly revenue was up 109.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.12 earnings per share. Analysts predict that Shire PLC will post $14.90 EPS for the current fiscal year.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.